Privatizing Biomedical Research - A 'Third Way'
Nature Biotechnology, Vol. 26, No. 1, pp. 31-36, 2008
6 Pages Posted: 15 Nov 2012 Last revised: 24 Feb 2014
The allocation of risks and benefits of publicly sponsored biomedical research is becoming increasingly skewed toward for-profit entities and against the public interest. A legitimate solution to this imbalance would be to levy compulsory government royalty fees on commercial products made possible by public efforts.
Keywords: technology, innovation, commercialization, medical research
Suggested Citation: Suggested Citation